Abstract
To estimate the cost-utility of bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) versus other triple combination antiretroviral therapies for naive patients over 18 years of age living with Human Immunodeficiency Virus type 1 (HIV-1) infection, without current or previous resistance to integrase strand transfer inhibitors, TAF or FTC, from the Colombian’s health system perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
